Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

Summary

The purpose of this study is to evaluate the efficacy and safety of the combination of ambrisentan and tadalafil in reducing mPAP to below 35mmHg in patients with moderate to severe Portopulmonary Hypertension (POPH) as a means to candidacy for liver transplantation.

Timeline

Start

2017-10-12

Primary completion

2018-11-01

Completion

2018-11-01

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of eligible participants and failure to meeting study enrollment.”

Drugs

Indications